Grace Therapeutics, Inc. (GRCE) - Total Liabilities
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has total liabilities worth $3.60 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Grace Therapeutics, Inc. to evaluate the company's liquid asset resilience ratio.
Grace Therapeutics, Inc. - Total Liabilities Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Grace Therapeutics, Inc. assets under control.
Grace Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Grace Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Big 5 Sporting Goods Corporation
NASDAQ:BGFV
|
USA | $482.30 Million |
|
MedMira Inc
V:MIR
|
Canada | CA$27.92 Million |
|
Tocvan Ventures Corp
F:TV3
|
Germany | €2.35 Million |
|
Ferroamp Elektronik AB
ST:FERRO
|
Sweden | Skr78.55 Million |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
Turkey | TL2.20 Billion |
|
Binh Duong Trade and Development JSC
VN:TDC
|
Vietnam | ₫2.83 Trillion |
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
India | Rs3.58 Billion |
|
WIIK Public Company Limited
BK:WIIK
|
Thailand | ฿833.60 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Grace Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GRCE net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grace Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual total liabilities of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $5.38 Million | -53.42% |
| 2024-03-31 | $11.56 Million | +3.48% |
| 2023-03-31 | $11.17 Million | -45.12% |
| 2022-03-31 | $20.35 Million | +199.35% |
| 2021-03-31 | $6.80 Million | -31.05% |
| 2020-03-31 | $9.86 Million | -61.86% |
| 2019-03-31 | $25.85 Million | +126.56% |
| 2018-03-31 | $11.41 Million | +1092.12% |
| 2016-03-31 | $957.12K | -69.91% |
| 2015-03-31 | $3.18 Million | -71.35% |
| 2014-03-31 | $11.10 Million | +364.58% |
| 2013-03-31 | $2.39 Million | +88.63% |
| 2012-03-31 | $1.27 Million | -75.83% |
| 2011-03-31 | $5.24 Million | +7.35% |
| 2010-03-31 | $4.88 Million | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more